184 related articles for article (PubMed ID: 36707207)
21. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
22. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
23. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
25. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
26. Early detection of ovarian cancer.
Badgwell D; Bast RC
Dis Markers; 2007; 23(5-6):397-410. PubMed ID: 18057523
[TBL] [Abstract][Full Text] [Related]
27. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
28. Molecular features as promising biomarkers in ovarian cancer.
Bukłaho PA; Kiśluk J; Wasilewska N; Nikliński J
Adv Clin Exp Med; 2023 Sep; 32(9):1029-1040. PubMed ID: 36920264
[TBL] [Abstract][Full Text] [Related]
29. Peritoneal biomarkers in the early detection of ovarian cancer.
Galea M; Gauci G; Calleja-Agius J; Schembri-Wismayer P
Minerva Ginecol; 2017 Feb; 69(1):84-99. PubMed ID: 27284942
[TBL] [Abstract][Full Text] [Related]
30. Early Detection of Ovarian Cancer.
Elias KM; Guo J; Bast RC
Hematol Oncol Clin North Am; 2018 Dec; 32(6):903-914. PubMed ID: 30390764
[TBL] [Abstract][Full Text] [Related]
31. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis.
Xiao Y; Bi M; Guo H; Li M
EBioMedicine; 2022 May; 79():104001. PubMed ID: 35439677
[TBL] [Abstract][Full Text] [Related]
32. Extracellular urinary microRNAs as non-invasive biomarkers of endometrial and ovarian cancer.
Hanžek A; Siatka C; Duc AE
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7981-7993. PubMed ID: 36914786
[TBL] [Abstract][Full Text] [Related]
33. HE4 in ovarian cancer: from discovery to clinical application.
Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
[TBL] [Abstract][Full Text] [Related]
34. Deciphering the molecular nature of ovarian cancer biomarker CA125.
Weiland F; Martin K; Oehler MK; Hoffmann P
Int J Mol Sci; 2012; 13(8):10568-10582. PubMed ID: 22949880
[TBL] [Abstract][Full Text] [Related]
35. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
36. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
[TBL] [Abstract][Full Text] [Related]
37. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
39. Relaxin as a potential diagnostic biomarker for ovarian cancer- A prospective study.
Gkrozou F; Pappa C; Tsonis O; Dimitriou E; Paschopoulos M
Eur J Obstet Gynecol Reprod Biol; 2021 May; 260():99-104. PubMed ID: 33752121
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer.
Ali FT; Soliman RM; Hassan NS; Ibrahim AM; El-Gizawy MM; Mandoh AAY; Ibrahim EA
PLoS One; 2022; 17(8):e0272308. PubMed ID: 35921382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
